Comparison · NCT00290771-sae
Imatinib 600 mg + Hydroxyurea 1000 mg vs Imatinib 1000 mg + Hydroxyurea 1000 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Imatinib 600 mg + Hydroxyurea 1000 mg vs Imatinib 1000 mg + Hydroxyurea 1000 mg: serious adverse events. Trial comparisons, record NCT00290771-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00290771-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.473 | 0.39 | 0.558 | wilson | |
| Risk in group 2 | 0.535 | 0.438 | 0.63 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0621 | -0.189 | 0.0675 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.884 | 0.683 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.78 | 0.462 | 1.32 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Imatinib 600 mg + Hydroxyurea 1000 mg than on Imatinib 1000 mg + Hydroxyurea 1000 mg | 16.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Imatinib 600 mg + Hydroxyurea 1000 mg | Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs. | 62 | 131 | EG000 |
| Group 2 | Imatinib 1000 mg + Hydroxyurea 1000 mg | Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs. | 53 | 99 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
- NCT number
- NCT00290771
- Phases
- PHASE2
- Conditions
- Recurrent Glioblastoma Multiforme (GBM)
- Interventions
- Imatinib tablets, Hydroxyurea capsules
- Lead sponsor
- Novartis
- Results first posted
- 2011-05-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00290771?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00290771-sae